Compared to controls, BRCA carriers had a trend toward worse LV posterior wall thickness (0.89cm卤0.15cm vs. 0.83cm卤0.16cm,p=0.06) although not statistically significant.#In women with newly diagnosed breast cancer and prior to treatment, LV-GLS was worse in BRCA1 and BRCA2 mutation ...
Germline genetic testing is increasingly being integrated into clinical care for women with breast cancer. "These women are often offered genetic testing prior to the initiation of any treatment," said Metcalfe. About 3% to 4% of women with breast cancer have a germline BRCA1 or BRCA2 mutation...
Cancer Control 9:457–465 Adem C, Reynolds C, Soderberg CL et al (2003) Pathologic characteristics of breast parenchyma in patients with hereditary ... YM Kirova,A Savignoni,B Sigal-Zafrani,... - 《Breast Cancer Research & Treatment》 被引量: 109发表: 2010年 Testing Adolescents for a He...
2). In the 2021 San Antonio Breast Cancer Conference (SABCS), a report from the Memorial Sloan Kettering Cancer Center showed that the median PFS of first-line CDK4/6 inhibitor combined with endocrine treatment for gBRCA2-mutated metastatic BC was shorter than that for gBRCA2 wild type BC...
None of the 13 patients had to withdraw from the talazoparib treatment due to side effects, which were limited mainly to fatigue and low blood counts. There were no grade 4 toxicities. Eight of the 13 had triple-negative disease, breast cancer that does not have HER2 or hormonal targets ...
Here, or onInstagram,Facebook,orYouTube. And learn more about Breast Cancer treatment, prevention, support & more. Join my free FB and Monthly Virtual Emotional Support Group, just for Women Cancer Warriors, Survivors, & Support People, "Growing Through Breast Cancer"...
Despite the initiation of treatment with irinotecan plus temozolomide on April 24, the patient died on July 2, 2013. The author believes that this case is the first report of a robust response to nab-paclitaxel monotherapy in triple-negative BRCA1-positive breast cancer, and that it supports ...
I use a feminist standpoint lens to explore the process by which BRCA-positive women came to socially construct and understand their risk for developing breast and/or ovarian cancer and the treatment options they elected post-testing. This study included in-depth interviews with 64 BRCA-positive ...
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field. Listen Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disp...
Veliparib has also shown promise in treatment-resistant breast cancer. In the I-SPY 2 trial of 71 women with triple-negative breast cancer, estimated pathologic complete response was better with veliparib plus carboplatin and paclitaxel than with standard paclitaxel (52% vs 26%)....